BML Capital Management LLC Acquires 662,079 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

BML Capital Management LLC raised its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,462,079 shares of the company’s stock after purchasing an additional 662,079 shares during the period. Atea Pharmaceuticals accounts for approximately 12.6% of BML Capital Management LLC’s holdings, making the stock its 3rd biggest holding. BML Capital Management LLC owned about 0.07% of Atea Pharmaceuticals worth $16,659,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in Atea Pharmaceuticals by 351.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,653 shares of the company’s stock valued at $29,000 after purchasing an additional 7,514 shares during the period. SG Americas Securities LLC lifted its position in Atea Pharmaceuticals by 23.3% during the 4th quarter. SG Americas Securities LLC now owns 42,521 shares of the company’s stock valued at $130,000 after purchasing an additional 8,024 shares during the period. Gladius Capital Management LP lifted its position in Atea Pharmaceuticals by 98.2% during the 3rd quarter. Gladius Capital Management LP now owns 8,581 shares of the company’s stock valued at $26,000 after purchasing an additional 4,251 shares during the period. GSA Capital Partners LLP lifted its position in Atea Pharmaceuticals by 41.9% during the 3rd quarter. GSA Capital Partners LLP now owns 278,286 shares of the company’s stock valued at $835,000 after purchasing an additional 82,208 shares during the period. Finally, Sectoral Asset Management Inc. increased its stake in shares of Atea Pharmaceuticals by 19.7% in the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company’s stock valued at $1,801,000 after acquiring an additional 98,924 shares during the last quarter. 86.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Andrea Corcoran sold 15,843 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the sale, the insider now directly owns 670,208 shares of the company’s stock, valued at approximately $2,573,598.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Andrea Corcoran sold 15,843 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the sale, the insider now directly owns 670,208 shares of the company’s stock, valued at approximately $2,573,598.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Wayne Foster sold 12,477 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $47,911.68. Following the completion of the sale, the chief accounting officer now directly owns 20,857 shares of the company’s stock, valued at $80,090.88. The disclosure for this sale can be found here. Insiders sold a total of 85,230 shares of company stock valued at $327,852 in the last ninety days. 14.50% of the stock is owned by insiders.

Atea Pharmaceuticals Price Performance

Shares of AVIR stock opened at $3.73 on Wednesday. The stock has a market cap of $313.95 million, a PE ratio of -2.27 and a beta of 0.16. The stock has a 50-day moving average of $3.99 and a 200-day moving average of $3.52. Atea Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $5.19.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). As a group, research analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.76 earnings per share for the current year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.